开运电竞

×
  • 销售咨讯

    中国:

    Email: marketing@czchengteng.com

    业务量了解和咨询线路查询:400-780-8018 (仅能业务询问,另外的情况说明请拨打办公电话川沙公司总部办公电话) 川沙总店座机号: +86 (21) 5859-1500

    海外:

    +1(781)535-1428(U.S.) 0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×
点击切换
Customer Center
客户中心

口服有效的ADAMTS-4/5抑制剂异吲哚啉酰胺衍生物,可治疗骨关节炎,本研究中部分化合物通过美迪西合成

2025-07-02
|
访问量:

Osteoarthritis (OA) is the most common chronic joint disease that affects the knee or hip with symptoms including joint pain and dysfunction. OA treatment is a highly unmet medical need. Development of a disease-modifying OA drug (DMOAD) is challenging with no approved drugs on the market. Inhibition of ADATMS-4/5 is a promising OA therapeutics to target cartilage degradation and potentially can reduce joint pain and restore its normal function.

Herein, researchers report the discovery and optimization of hydantoin-type ADAMTS-4/5 inhibitors featured by a novel isoindoline amide scaffold for the treatment of osteoarthritis. The most promising compound 18 showed high in vitro potency as an ADAMTS-4/5 inhibitor, good druglike properties, and oral bioavailability. Molecule 18 exhibited clear dose-dependent efficacy in two independent in vivo efficacy studies. Part of the compound synthesis was performed at Medicilon.

86.png

Reference:

各种相关要闻
×
搜索验证
点击切换